Adaptive mutability of colorectal cancers in response to targeted therapies
Open accessThe DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
A cross-kingdom tale of drug resistance: Physicians who treat bacterial infections and those who treat cancer often face a common challenge: the development of drug resistance. It is well known that when bacteria are exposed to antibiotics, they temporarily increase their mutation rate, thus increasing the chance that a descendant antibiotic-resistant cell will arise. Russo et al. now provide evidence that cancer cells exploit a similar mechanism to ensure their survival after drug exposure (see the Perspective by Gerlinger). They found that human colorectal cancer cells treated with certain targeted therapies display a transient up-regulation of errorprone DNA polymerases and a reduction in their ability to repair DNA damage. Thus, like bacteria, cancer cells can adapt to therapeutic pressure by enhancing their mutability. Science , this issue p. 1473 ; see also p. 1458
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This observation may be due to a more potent treatment effect with the combination of divarasib and cetuximab imposing a stronger selective pressure and/or potentially increasing the adaptive mutability of the residual cancer cells30.”
From Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial (2024) · cites this paper as [30]
Citations
Cites
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179
mTOR Signaling in Growth, Metabolism, and Disease
Saxton, R. A., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.02.004 · Cited by 7,555
GENCODE: The reference human genome annotation for The ENCODE Project
Harrow, J., Frankish, A., Gonzalez, J. M., Tapanari, E., Diekhans, M., Kokocinski, F., Aken, B. L., Barrell, D., Zadissa, A., Searle, S., et al. (2012) · Genome Research · doi:10.1101/gr.135350.111 · Cited by 4,585
Mutations of bacteria from virus sensitivity to virus resistance
Luria, S. E., & Delbrück, M. (1943) · Genetics · doi:10.1093/genetics/28.6.491 · Cited by 3,894
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
Self-citationEmergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889
Self-citationThe molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Diaz Jr, L. A., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., Allen, B., Bozic, I., Reiter, J. G., Nowak, M. A., et al. (2012) · Nature · doi:10.1038/nature11219 · Cited by 1,713
γH2AX: a sensitive molecular marker of DNA damage and repair
Mah, L.-J., El-Osta, A., & Karagiannis, T. C. (2010) · Leukemia · doi:10.1038/leu.2010.6 · Cited by 1,557
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
Kopetz, S., Grothey, A., Yaeger, R., Van Cutsem, E., Desai, J., Yoshino, T., Wasan, H., Ciardiello, F., Loupakis, F., Hong, Y. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908075 · Cited by 1,491
Cited by
Items 201–300 of 435
Roles for growth factors and mutations in metastatic dissemination
Nataraj, N. B., Marrocco, I., & Yarden, Y. (2021) · Biochemical Society Transactions · doi:10.1042/bst20210048 · Cited by 17
Pan-cancer analysis identifies YTHDF2 as an immunotherapeutic and prognostic biomarker
Liu, W., Liu, C., You, J., Chen, Z., Qian, C., Lin, W., Yu, L., Ye, L., Zhao, L., & Zhou, R. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.954214 · Cited by 17
“MMR is an important factor related to genome stability and integrity (Fishel, 2015; Russo et al., 2019).”
BackgroundLinghu, D., Song, J., Gu, L., Liu, C., Liu, B., Yang, R., Chen, Q., Yao, J., Manickam, S. P., Sundhar, N., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010926 · Cited by 18
Modulating environmental signals to reveal mechanisms and vulnerabilities of cancer persisters
Sun, X., Bieber, J. M., Hammerlindl, H., Chalkley, R. J., Li, K. H., Burlingame, A. L., Jacobson, M. P., Wu, L. F., & Altschuler, S. J. (2022) · Science Advances · doi:10.1126/sciadv.abi7711 · Cited by 15
Alves, J. M., Prado‐Lòpez, S., Tomás, L., Valecha, M. V., Estévez‐Gómez, N., Alvariño, P., Geisel, D., Modest, D. P., Sauer, I. M., Pratschke, J., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215767 · Cited by 18
Single-cell phylogenies reveal changes in the evolutionary rate within cancer and healthy tissues
Borgsmüller, N., Valecha, M. V., Kuipers, J., Beerenwinkel, N., & Posada, D. (2023) · Cell Genomics · doi:10.1016/j.xgen.2023.100380 · Cited by 17
“37,43 Identifying evolutionary rate changes in cell populations is therefore critical to understand somatic evolution in cancer and healthy tissues.”
Roazzi, L., Patelli, G., Bencardino, K. B., Amatu, A., Bonazzina, E. F., Tosi, F., Amoruso, B., Bombelli, A., Mariano, S., Stabile, S., et al. (2024) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2024.02.001 · Cited by 17
Self-citationKulesza, A. J., Couty, C., Lemarre, P., Thalhauser, C. J., & Cao, Y. (2024) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-024-09930-x · Cited by 19
“This is because high drug exposure can lead to increased mutation rates, genomic instability, and selection of pre-existing resistant clones, contributing to the development of resistance [74].”
Li, M., Li, W., Yang, X., Wang, H., Peng, Y., Yin, J., Lu, Y., Liu, L., Shang, J., & Zhao, Q. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118368 · Cited by 18
Host-Dependent Phenotypic Resistance to EGFR Tyrosine Kinase Inhibitors
Haga, Y., Marrocco, I., Noronha, A., Uribe, M. L., Nataraj, N. B., Sekar, A., Garcia, D. D., Borgoni, S., Lindzen, M., Giri, S., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3555 · Cited by 16
“However, in the absence of secondary EGFR mutations, PC9DR cells cannot transform to a permanent TKI-resistant state, which is irreversibly rewired as a result of drug-induced adaptive mutability (23).”
BackgroundRousseau, B., Patel, M., Artz, O., Vlachos, G., Patel, S. D., Hayatt, O., Argilés, G., Foote, M. B., Luo, L., Shah, R., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.05.010 · Cited by 18
Self-citationMapping intratumor heterogeneity across layers for advancing immunotherapy
Marine, J., Bartok, O., Sagie, S., Vitiello, P. P., Bardelli, A., Weller, C., Chang, T., Tonelli, C., Spranger, S., Ruppin, E., et al. (2026) · Cell · doi:10.1016/j.cell.2026.03.025 · Cited by 16
Self-citationThe epigenome and the many facets of cancer drug tolerance
Moore, P. C., Henderson, K. W., & Classon, M. (2023) · Advances in cancer research · doi:10.1016/bs.acr.2022.12.002 · Cited by 15
Kumar, S., Gahramanov, V., Patel, S. H., Yaglom, J. A., Kaczmarczyk, L. S., Alexandrov, I. A., Gerlitz, G., Salmon‐Divon, M., & Sherman, M. Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108717 · Cited by 17
Mechanisms of resistance to EGFR-targeted therapies in colorectal cancer: more than just genetics
Parseghian, C. M., Eluri, M., Kopetz, S., & Raghav, K. P. S. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1176657 · Cited by 16
“However, an alternative hypothesis known as adaptive mutability has been proposed as a mechanism implicated in this progression (Russo et al., 2019).”
BackgroundClonal Neoantigen: Emerging “Mechanism-based” Biomarker of Immunotherapy Response
Nemunaitis, J. J., Stanbery, L., Willoughby, D., Bognar, E., Brun, S., Walter, A., Monk, B. J., Rocconi, R. P., Choucair, K., & Coleman, R. L. (2023) · Cancers · doi:10.3390/cancers15235616 · Cited by 15
“Many examples of induced resistance to clinical interventions have been demonstrated [6–9].”
BackgroundTrigos, A., Bongiovanni, F., Zhang, Y., Zethoven, M., Tothill, R. W., Pearson, R. B., Papenfuss, A. T., & Goode, D. L. (2024) · Genome biology · doi:10.1186/s13059-024-03247-1 · Cited by 15
“An example of the functional impacts is the stress-induced activation of error-prone DNA repair mechanisms conserved with bacteria in a range of tumors, facilitating drug resistance [17, 18], and leaving detectable mutational signatures [19, 20].”
BackgroundZhang, C., Lu, Y., Wang, M., Chen, B., Xiong, F., Mitsopoulos, C., Rossanese, O. W., Li, X., & Clarke, P. A. (2024) · Oncogene · doi:10.1038/s41388-024-03171-5 · Cited by 16
Genetic Determinants of Somatic Selection of Mutational Processes in 3,566 Human Cancers
Guo, J., Zhou, Y., Xu, C., Chen, Q., Sztupinszki, Z. M., Börcsök, J., Xu, C., Ye, F., Tang, W., Kang, J., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0086 · Cited by 16
“S5), which is consistent to the previous reports that treatment influence the 310 mutability of cancer (10,34).”
BackgroundResultFumasoni, M., & Murray, A. W. (2021) · PLoS Genetics · doi:10.1371/journal.pgen.1009875 · Cited by 13
Switching off DNA repair—how colorectal cancer evades targeted therapies through adaptive mutability
Fahrer, J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0120-3 · Cited by 14
From single gene analysis to single cell profiling: a new era for precision medicine
Martino, M. T. D., Meschini, S., Scotlandi, K., Riganti, C., Smaele, E. D., Zazzeroni, F., Donadelli, M., Leonetti, C., & Caraglia, M. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01549-3 · Cited by 14
Cheng, A., Rao, Q., Liu, Y., Huang, C., Li, J., Huo, C., Lin, Z., & Lu, H. (2022) · Gynecologic Oncology · doi:10.1016/j.ygyno.2022.10.011 · Cited by 12
A perspective on tumor radiation resistance following high-LET radiation treatment
Rajpurohit, Y. S., Sharma, D. K., Lal, M., & Soni, I. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05757-8 · Cited by 16
“Recent research has highlighted the role of TLSs in adaptive mutability to evade targeted drugs against EGFR/ BRAF (Crisafulli and Siravegna 2023; Russo et al. 2019).”
BackgroundSpeaker Recognition Based on Dung Beetle Optimized CNN
Guo, X., Qin, X., Zhang, Q., Zhang, Y., Wang, P., & Fan, Z. (2023) · Applied Sciences · doi:10.3390/app13179787 · Cited by 11
New Insight to Overcome Tumor Resistance: An Overview from Cellular to Clinical Therapies
Mitola, G., Falvo, P., & Bertolini, F. (2021) · Life · doi:10.3390/life11111131 · Cited by 16
Su, Y., Liu, C., Lu, X., Li, G., Shao, S., Kong, Y., Lee, J. W., Ng, R. H., Wong, S. K., Robert, L., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/724740 · Cited by 12
Roca, M. S., Lombardi, R., Testa, C., Iannelli, F., Grumetti, L., Moccia, T., Barile, V., Addi, L., Memoli, D., Leone, A., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07902-8 · Cited by 15
“Recent studies in many models of cancer, including CRC, also suggest that in addition to canonical acquired resistance mechanisms, de novo resistant clones can develop due to the emergence of a subpopulation of drug-tolerant persistent (DTP) cells [8, 9].”
IL-1 and senescence: Friends and foe of EGFR neutralization and immunotherapy
Romaniello, D., Gelfo, V., Pagano, F., Sgarzi, M., Morselli, A., Girone, C., Filippini, D. M., D’Uva, G., & Lauriola, M. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1083743 · Cited by 15
Guo, X., Bian, X., Li, Y., Zhu, X. M., & Zhou, X. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167098 · Cited by 16
Harrold, E. C., Keane, F., Walch, H. S., Chou, J. F., Sinopoli, J. C., Palladino, S., Al-Rawi, D. H., Chadalavada, K., Manca, P., Chalasani, S. B., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-4005 · Cited by 13
“The induction of an enhanced mutagenesis through downregulation of mismatch repair and homologous recombination DNA repair genes and upregulation of error-prone polymerases in colorectal cancers during targeted therapy has been described as a mechanism underlying drug resistance (42).”
An Observatory for the MET Oncogene: A Guide for Targeted Therapies
Altintas, D. M., & Comoglio, P. M. (2023) · Cancers · doi:10.3390/cancers15184672 · Cited by 11
The European Union and personalised cancer medicine
Hickman, J. A., Tannock, I. F., Meheus, L., & Hutchinson, L. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.03.013 · Cited by 11
Yeh, C., Artz, O., Zhang, H., Karnoub, E.-R. R., Ntiamoah, P., Weipert, C. M., Walch, H. S., Harrold, E. C., Keane, F., Chalasani, S. B., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-2566 · Cited by 15
“…to targeted therapy in colorectal cancer suggest that cancer cells evade the effects of treatment by inducing a program of enhanced mutagenesis (3), and analyses of patient samples at the time of disease progression commonly identify the emergence of multiple resistance alterations within the…”
Polymorphisms of DNA Repair Genes in Thyroid Cancer
Gielecińska, A., Kciuk, M., Kołat, D., Kruczkowska, W., & Kontek, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115995 · Cited by 10
“EGFR may down-regulate DNA repair genes from the MMR and HR systems, increasing the likelihood of polymerase errors [120].”
BackgroundLiu, M., Wang, T., & Li, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020625 · Cited by 10
“They are also involved in processes such as response to growth factors, angiogenesis, regulation of epithelial-to-mesenchymal transition, and protein kinase B signaling, all of which play critical roles in CRC tumorigenesis and progression [44–46].”
Subclonal response heterogeneity to define cancer organoid therapeutic sensitivity
Kratz, J. D., Rehman, S., Johnson, K. A., Gillette, A. A., Sunil, A., Favreau, P. F., Pasch, C. A., Miller, D. D., Zarling, L. C., Yeung, A. H., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-96204-2 · Cited by 21
“This work provides a framework to characterize line specific adaptive mutability in response to targeted therapy 40 and has been integrated into the prospective investigation of EGFR inhibition for advanced CRC (NCT04587128).”
Deciphering molecular pathways in urological cancers: A gateway to precision therapeutics
Hushmandi, K., Farahani, N., Einollahi, B., Salimimoghadam, S., Alimohammadi, M., Liang, L., Liu, L., & Sethi, G. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.06.009 · Cited by 13
Ni, J., Zhou, R., Cheng, X., Xu, X., Guo, W., & Chen, X. (2020) · Journal of Ovarian Research · doi:10.1186/s13048-020-00629-4 · Cited by 11
“PARPi-resistant clones have been shown to be affected by the tumor burden [18, 19].”
BackgroundSeita, A., Nakaoka, H., Okura, R., & Wakamoto, Y. (2021) · PLoS ONE · doi:10.1371/journal.pone.0236534 · Cited by 15
“It is an intriguing question whether the slow-cycling phenotype is a prerequisite for the acquisition of stronger drug resistance, possibly mediated by drastic changes in metabolic states or triggering adaptive mutations [41, 42].”
BackgroundKobori, T., Tameishi, M., Tanaka, C., Urashima, Y., & Obata, T. (2021) · PLoS ONE · doi:10.1371/journal.pone.0250889 · Cited by 10
Torlot, L., Jarząb, A., Albert, J., Pók-Udvari, Á., Stahler, A., Holch, J. W., Gerlinger, M., Heinemann, V., Klauschen, F., Kirchner, T., et al. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04416-0 · Cited by 10
Genetic and non‐genetic drug resistance: Darwin or Lamarck?
Russo, M. (2024) · Molecular Oncology · doi:10.1002/1878-0261.13601 · Cited by 12
“The sustained exposure to drug-induced stress further induces a temporary increase of the mutation rate of surviving persister cells, thus increasing the probability that alterations conferring resistance might be acquired [8,14].”
BackgroundSelf-citationZhang, Z., Li, Y., Shi, R., Jia, C., Xu, S., Zhu, G., Cao, P., Huang, H., Li, X., Zhang, H., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06796-2 · Cited by 11
“It was also demonstrated that ROS levels and DNA damage increase following exposure of cells to cetuximab [23].”
BackgroundThe molecular mechanisms of chemotherapeutic resistance in tumors (Review)
Weng, X., Zeng, W.-H., Zhong, L., Xie, L., Ge, W.-J., Lai, Z., Qin, Q., Liu, P., Cao, D., & Zeng, X. (2024) · Oncology Reports · doi:10.3892/or.2024.8816 · Cited by 10
Qin, B., Jiao, X., Wang, Z., Liu, K., Ling, Y., Wu, Y., & Zang, Y. (2025) · BMJ · doi:10.1136/bmj-2025-086026 · Cited by 13
“In addition, the most promising synergistic antitumor effect emerged from the combination of PD-1 inhibitors and EGFR/BRAF blockade, 80-82 which was associated with the highest objective response rate across the evaluated regimens.”
Lü, N., Guan, X., Zhu, J., Li, Y., & Zhang, J. (2023) · Cancers · doi:10.3390/cancers15184497 · Cited by 11
“However, predictive models target images of the entire tumor, and not a localized site [57,58].”
BackgroundTumor-wide RNA splicing aberrations generate immunogenic public neoantigensPreprint
Kwok, D. W., Stevers, N. O., Nejo, T., Chen, L. H., Etxeberría, I., Jung, J., Okada, K., Cove, M. C., Lakshmanachetty, S., Gallus, M., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.19.563178 · Cited by 9
Single‑cell multi‑omics advances in lymphoma research (Review)
Jin, C., Zhou, D., Li, J., Bi, L., & Li, L. (2023) · Oncology Reports · doi:10.3892/or.2023.8621 · Cited by 9
Bioinspired nanomedicines for the management of osteosarcoma: Recent progress and perspectives
Cui, K., Ren, F., Yu, J., & Pan, H. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.101607 · Cited by 12
Function and mechanism of lactylation in health and diseases: a comprehensive review
Yang, Y., Deng, L., Zhang, H., Hu, J., Li, J., Wang, L., & Gan, X. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000002623 · Cited by 10
Mismatch Repair as a Dynamic and Clinically Actionable Vulnerability in Cancer
Piumatti, E., Vitiello, P. P., Amodio, V., Bardelli, A., & Germano, G. (2025) · Cancer Research · doi:10.1158/0008-5472.can-25-2255 · Cited by 14
Self-citationDNA fragmentation factor B suppresses interferon to enable cancer persister cell regrowth
Williams, A. F., Gervasio, D. A. G., Turkal, C. E., Stuhlfire, A. E., Wang, M. X., Mauch, B. E., Plawat, R., Nguyen, A. H., Paw, M. H., Hairani, M., et al. (2025) · Nature Cell Biology · doi:10.1038/s41556-025-01810-x · Cited by 12
“…we performed whole-exome sequencing on the wild-type DFFB and DFFB-KO A375 cells subjected to 7 weeks of dabrafenib and trametinib treatment, which revealed a variety of acquired mutations, supporting recent reports of per-sister cell stress-induced mutagenesis 3,25 (Supplementary Table 4).”
Song, L., Cai, J., Zhu, G., Zhang, P., Chen, S., Quan, B., Du, J.-X., Cai, Y., Song, L., Zhou, J., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.218188 · Cited by 8
An evolutionary explanation for antibiotics’ association with increased colon cancer risk
Voskarides, K. (2022) · Evolution Medicine and Public Health · doi:10.1093/emph/eoac018 · Cited by 8
“[46] showed that this is the case with colon cancer cells under anticancer therapy stress.”
BackgroundNotch-3 affects chemoresistance in colorectal cancer via DNA base excision repair enzymes
George, D. C., Bertrand, F. E., & Sigounas, G. (2024) · Advances in Biological Regulation · doi:10.1016/j.jbior.2024.101013 · Cited by 8
Sun, L., Fan, G., Zhang, Z., Chang, D., Zhang, X., Zhang, T., Geng, J., Zhang, X., Lin, M., Chen, H., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115269 · Cited by 9
Valenzuela, G., Burotto, M., Marcelain, K., & González‐Montero, J. (2022) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v14.i9.1654 · Cited by 9
Ma, G., Jia, H., Li, Z., Zhang, X., Wang, L., Zhang, Z., Xiao, Y., Liang, Z., Li, D., Chen, Y., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-0039 · Cited by 11
Rojas, M., Manzi, M., Madurga, S., Velásquez, F. E. G., Romero, M. A., Marín, S., Cascante, M., & Maurel, J. (2025) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2025.1002337 · Cited by 8
Luan, W.-Y., Zhao, Q., Zhang, Z., Xu, Z.-X., Lin, S.-X., & Miao, Y. (2025) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v17.i10.110661 · Cited by 9
“Importantly, such resistance can also emerge during treatment; EGFR or BRAF inhibitors may induce DNA damage, increase mutational burden, or trigger MSI, enabling tumor escape[53].”
Mariotto, E., Rampazzo, E., Bortolozzi, R., Rruga, F., Zeni, I., Manfreda, L., Marchioro, C., Canton, M., Cani, A., Magni, R., et al. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01679-7 · Cited by 7
“However, despite MB-R cells were characterized by a limited non-recurrent CNE, additional analyses would be needed to rule out potential mutational events responsible for the observed phenotype, as widely reported in several other neoplastic contexts [5, 34–36].”
BackgroundAnselmino, L., Malizia, F., Avila, A., Laluce, N. C., Mamberto, M., Zanotti, L. C., Farré, C., Sauzeau, V., & Menacho-Márquez, M. (2024) · Cells · doi:10.3390/cells13211776 · Cited by 10
Jameson, N. M., Kim, D., Lee, C., Skrable, B., Shea, A., Guo, X., Izadi, H., Abed, M., Harismendy, O., Ma, J., et al. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0411 · Cited by 9
“Inhibition of these oncogenic drivers might be hypothesized to reduce these RS phenotypes, yet para-doxically it has also been demonstrated that inhibition of oncogenic drivers like KRAS can drive high levels of CIN and RS (17, 23, 24).”
Gao, Q.-M., Zhu, X., Chen, M., Xia, R., & Zhang, Q. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1541675 · Cited by 7
“Furthermore, ROS can induce mutagenic break repair and activate the SOS response by damaging DNA bases, which interrupts replication and triggers a critical transition from high-fi delity to error-prone DNA polymerases, ultimately leading to an increase in carcinogenic mutations (19, 20).”
Bronder, D., & Bakhoum, S. F. W. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.202012017 · Cited by 6
“Interestingly, Russo et al (2019) observed that colon cancer cells downregulated DNA repair genes and upregulated mutagenic polymerases in response to targeted therapy.”
Chen, T., Zhang, Q., Song, Y., Isak, A. N., Tang, X., Wang, H., Ma, Z., Sun, F., Pan, Q., & Zhu, X. (2021) · Nanoscale Horizons · doi:10.1039/d1nh00350j · Cited by 7
Cell Adaptive Fitness and Cancer Evolutionary Dynamics
Derbal, Y. (2023) · Cancer Informatics · doi:10.1177/11769351231154679 · Cited by 7
Zeng, X., Sun, L., Ling, X., Jiang, Y., Shen, J., Liang, L., & Zhang, X. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1170526 · Cited by 7
Valcz, G., Buzás, E. I., Gatenby, R. A., Újvári, B., & Molnar, B. A. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189088 · Cited by 9
Integrating Subclonal Response Heterogeneity to Define Cancer Organoid Therapeutic SensitivityPreprint
Kratz, J. D., Rehman, S., Johnson, K. A., Gillette, A. A., Sunil, A., Favreau, P. F., Pasch, C. A., Miller, D. D., Zarling, L. C., Yeung, A. H., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.10.15.464556 · Cited by 7
Graham, E., Rampazzo, L., Leung, C. W. B., Wall, J., Gerőcz, E. Z., Liskovykh, M. A., Goncharov, N., Saayman, X., Gündoğdu, R., Kanemaki, M. T., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115259 · Cited by 9
Antibacterial compounds against non-growing and intracellular bacteria
Kaldalu, N., Bērziņš, N., Fick, S. B., Sharma, A., Andersson, N. C., Aedla, J., Hinnu, M., Puhar, A., Hauryliuk, V., & Tenson, T. (2025) · npj Antimicrobials and Resistance · doi:10.1038/s44259-025-00097-0 · Cited by 6
“Reduced DNA repair capacity accompanied by increased mutagenesis have been observed as a survival strategy both in certain tumor cells 82 and in bacteria, where error-prone mutagenesis is induced in response to antibiotics 83,84 .”
Tan, S., Zhang, W., Ding, Y., Liu, J., Zhu, M., Luo, X., Cai, J., & Zeng, H. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1772701 · Cited by 11
“For example, B-Raf proto-oncogene, serine/threonine kinase (BRAF) inhibitor drug-resistant cells sustain proliferation through upregulated OXPHOS or enhanced glycolysis (26, 27).”
State of the art and future perspectives
Facchinetti, F., & Friboulet, L. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821774-0.00009-7 · Cited by 9
Ding, J., Ji, X., Liu, L., Chen, D., Luo, N., Yu, X., & Guo, F. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04738-7 · Cited by 7
Gut microbiota–lncRNA/circRNA crosstalk: implications for different diseases
Zhang, L., Li, X., Gao, H., Chang, W., & Li, P. (2024) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2024.2375516 · Cited by 11
“CRC patients usually do not respond to current immune checkpoint therapy (Russo et al. 2019).”
Blackstone, N. W., & Gutterman, J. U. (2020) · BioEssays · doi:10.1002/bies.202000160 · Cited by 6
“In many ways, their behavior suggests atavistic unicellular organisms,[5,8,51] exhibiting striking parallels to yeasts—polyphyletic, unicellular, fast-replicating, and predominately glycolytic.”
BackgroundEscape from G1 arrest during acute MEK inhibition drives the acquisition of drug resistance
Channathodiyil, P., May, K., Segonds-Pichon, A., Smith, P. D., Cook, S. J., & Houseley, J. M. (2022) · NAR Cancer · doi:10.1093/narcan/zcac032 · Cited by 6
“Reduced expression of high-fidelity DNA replication and repair genes has been observed in drug-arrested cell populations (28,30), which suggests that the sporadic entry of drug-treated cells into S phase may occur when replication factors are limited.”
BackgroundSystematic pan-cancer analysis identifies cGAS as an immunological and prognostic biomarker
Chen, P., Yang, X., Wang, P., He, H., Chen, Y., Yu, L., Fang, H., Wang, F., & Huang, Z. (2023) · Annals of Translational Medicine · doi:10.21037/atm-22-6318 · Cited by 5
“MMR has received considerable attention as an important factor in genome stability and integrity (51,52).”
Oncolytic viruses and cancer treatment
Španielová, H., & Brdička, R. (2023) · Klinicka onkologie · doi:10.48095/ccko202312 · Cited by 7
Celeste, F., & Powers, S. (2024) · Cancers · doi:10.3390/cancers16051001 · Cited by 8
“Moreover, given the observed elevation of repair enzymes and error-prone DNA polymerases in persister cells [24–27], we included an examination of these enzymes in our analysis.”
Popovic, M. M., Talarico, O. S., van den Hoff, J., Kunin, H. S., Zhang, Z., Lafontaine, D., Doğan, S., Leung, J., Kaye, E., Czmielewski, C., et al. (2020) · EJNMMI Research · doi:10.1186/s13550-020-00707-0 · Cited by 7
“Additionally, patients treated with targeted therapies, including EGFR, HER2 and BRAF targeting combinations, have been reported to develop KRAS mutations at resistance, often in a heterogeneous pattern involving some lesions [18, 19].”
Properties and gene expression profiling of acquired radioresistance in mouse breast cancer cells
Feng, Q. F., Fan, Q., Yu, K. N., Almahi, W. A., Kong, P., Yang, M., Cao, W., Nie, L., Chen, G., & Han, W. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-4667 · Cited by 5
“drug treatment leads to reversible drug resistance, while longterm drug treatment leads to permanent drug resistance (45).”
BackgroundNon‐genetic and genetic rewiring underlie adaptation to hypomorphic alleles of an essential gene
Targa, A., Larrimore, K. E., Wong, C. K., Chong, Y. L., Fung, R., Lee, J., Choi, H., & Rancati, G. I. (2021) · The EMBO Journal · doi:10.15252/embj.2021107839 · Cited by 4
CXCL13 as a Prognostic Biomarker and Modulator of the Tumor Microenvironment in Colorectal Cancer
Guo, F., Chen, W., Yan, Y., Yao, C., Zhang, R., Shen, C., Cui, Y., Peng, Y. S., Hong, J., Chen, H., et al. (2025) · Journal of Digestive Diseases · doi:10.1111/1751-2980.70001 · Cited by 6
“However, only 15%–20% of CRC patients harbor MSI-H or MMRd tumors [8, 9], and little clinical benefit is obtained in microsatellite-stable (MSS)/MMR-proficient (MMRp) CRC cases from ICIs [10, 11].”
Wang, Z., Jin, M., Zhai, L., Huang, B., Jin, X., Wang, X., Boudemia, A. E., Yang, X., Wei, Z., He, Y., et al. (2026) · Molecular Cell · doi:10.1016/j.molcel.2026.01.020 · Cited by 6
Sagawa, T., Sato, Y., Hirakawa, M., Hamaguchi, K., Tamura, F., Nagashima, H., Fujikawa, K., Okamoto, K., Kawano, Y., Sogabe, M., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1203296 · Cited by 5
“This altered protein expression returns to baseline when the stress of the targeted therapy is removed, suggesting that this was a transient process (19).”
BackgroundOptimal dosing of anti-cancer treatment under drug-induced plasticity
Gunnarsson, E. B., Magnússon, B. V., & Foo, J. (2025) · npj Systems Biology and Applications · doi:10.1038/s41540-025-00571-5 · Cited by 11
“While genetic mutations have long been understood to be important drivers of cancer evolution, it has more recently become clear that epigenetic mechanisms such as methylation and acetylation are suf fi cient to ful fi ll the traditional hallmarks of cancer 3 – 6 .”
Clinicopathological and molecular features of colorectal cancer with synchronous adenoma
Sun, X., Zhao, D., Long, S., Chen, S., Cai, Q., & Yao, S. (2020) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2020.1795922 · Cited by 5
Pignochino, Y., Crisafulli, G., Giordano, G., Merlini, A., Berrino, E., Centomo, M. L., Chiabotto, G., Brusco, S., Basiricò, M., Maldi, E., et al. (2021) · Cancers · doi:10.3390/cancers13246295 · Cited by 7
“TMB was calculated from WES data, taking into consideration somatic mutations after data normalization on the specific covered target region of each sample [29,30].”
MethodSelf-citationLine by Line: Distinct Patterns of Anti-EGFR Antibody Resistance by Line of Therapy
Corcoran, R. B. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.01922 · Cited by 5
Detection of endogenous translesion DNA synthesis in single mammalian cells
Egger, T., Aze, A., & Maiorano, D. (2023) · Cell Reports Methods · doi:10.1016/j.crmeth.2023.100501 · Cited by 8
“By facilitating proliferation under DNA damage and increasing genetic diversity, TLS is exploited by cancer cells to adapt to therapy, thus escaping apoptosis, and has recently drawn much attention as a pathway to target so as to sensitize cancer cells to therapy.(2,3) Y-family TLS pols (h, i, k, andRev1) are implicat…”
BackgroundGao, X., Qian, J., Zhang, Y., Wang, H., Cui, J., & Yang, Y. (2023) · Proteome Science · doi:10.1186/s12953-023-00216-7 · Cited by 5
“Past studies on the underlying mechanism of drug resistance mainly focus on biochemical and metabolic signals within tumor microenvironment, such as DNA mutations and metabolic reprogramming, etc. [9–12].”
BackgroundTransmissible cancers, the genomes that do not melt down
Bramwell, G., DeGregori, J. V., Frédéric Thomas, A., & Újvári, B. (2024) · Evolution · doi:10.1093/evolut/qpae063 · Cited by 5
Gay, C. M., Parseghian, C. M., & Byers, L. A. (2020) · Cancer Cell · doi:10.1016/j.ccell.2019.12.005 · Cited by 6
Milanese, C., & Mastroberardino, P. G. (2020) · Molecular & Cellular Oncology · doi:10.1080/23723556.2020.1733383 · Cited by 5
“A further possibility stems from recent evidence supporting the concept that development of chemoresistance may parallel development of antibiotic resistance in bacteria.(7) Here, in initial phases, growth – and thus macromolecular synthesis – is highly reduced in resistant cells.”
BackgroundCatania, F., Rothering, R., & Vitali, V. (2021) · Genome Biology and Evolution · doi:10.1093/gbe/evab263 · Cited by 6
Ghoderao, P., Kwiatkowska-Borowczyk, E. P., Sahare, S. H., & Dams‐Kozlowska, H. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17111428 · Cited by 5
Daley, B. R., Theard, P. L., Hughes, J. M., Finniff, B. A., Hofmann, M. H., Kostyrko, K., Schenk, R. L., Vieira, H. M., Askew, J. W., Lewis, R. E., et al. (2025) · Science Signaling · doi:10.1126/scisignal.aea2788 · Cited by 4
Metadata
- Authors
- Russo, M., Crisafulli, G., Sogari, A., Reilly, N. M., Arena, S., Lamba, S., Bartolini, A., Amodio, V., Magrì, A., Novara, L., Sarotto, I., Nagel, Z. D., Piett, C. G., Amatu, A., Sartore-Bianchi, A., Siena, S., Bertotti, A., Trusolino, L., Corigliano, M., Gherardi, M., Lagomarsino, M. C., Di Nicolantonio, F., & Bardelli, A.
- Affiliations
- Candiolo Cancer Institute (IT)
- Fondazione Piemontese per la Ricerca sul Cancro Onlus (IT)
- Harvard University (US)
- University of Milan (IT)
- Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, 20162 Milan, Italy.
- Candiolo Cancer Institute, FPO–IRCCS, Candiolo (TO) 10060, Italy.
- Corresponding author
- Russo, Mariangela
- Bardelli, Alberto
- ORCID
- Russo, Mariangela
- Crisafulli, Giovanni
- Sogari, Alberto
- Reilly, Nicole M.
- Arena, Sabrina
- Lamba, Simona
- Bartolini, Alice
- Amodio, Vito
- Magrì, Alessandro
- Novara, Luca
- Sarotto, Ivana
- Nagel, Zachary D.
- Piett, Cortt G.
- Amatu, Alessio
- Sartore-Bianchi, Andrea
- Siena, Salvatore
- Bertotti, Andrea
- Trusolino, Livio
- Corigliano, Mattia
- Gherardi, Marco
- Lagomarsino, Marco Cosentino
- Di Nicolantonio, Federica
- Bardelli, Alberto
- Venue
- Science
- Published
- 2019-12-20
- Volume
- 366
- Issue
- 6472
- Pages
- 1473-1480
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2987148655
- Cited by
- 433
- References
- 62
- Citations by year
- 2026: 41 · 2025: 55 · 2024: 60 · 2023: 70 · 2022: 76 · 2021: 72 · 2020: 57 · 2019: 2
- FWCI
- 21.60
- Type
- journal article
- Language
- en
- Open access
- Licence
- other-oa
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Funders
- H2020 Health (635342-2 MoTriColor, no. 754923 COLOSSUS)
- Ministero della Salute (Ricerca Corrente 2019 RC2019)
- Associazione Italiana per la Ricerca sul Cancro (9970 Extension program, IG. 16788, ID. 21091, ID.21091, AIRC IG 2018 - ID. 21923)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- colorectal cancer, drug resistance, targeted therapy, EGFR inhibition, BRAF inhibition, DNA mismatch repair, homologous recombination, error-prone DNA polymerases, microsatellite instability, drug-tolerant persister cells, DNA damage, patient-derived xenografts
- MeSH terms
- Adaptation, Biological, Humans, Selection, Genetic, Colorectal Neoplasms, Down-Regulation, Mutagenesis, Drug Resistance, Neoplasm, Proto-Oncogene Proteins B-raf, DNA Mismatch Repair, Molecular Targeted Therapy, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.